KalVista Pharmaceuticals

KALV

Market cap $792M

FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new data from its sebetralstat clinical trial program presented at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting and the Western Society of Allergy, Asthma & Immunology (WSAAI) 63rd Annual Scientific Session. The presentations demonstrate a significant shift in how patients manage hereditary angioedema (HAE) attacks when provided with.

FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at each of the following upcoming investor conferences: TD Cowen 46th Annual Healthcare Conference on Wednesday, March 4, 2026, at 11:10 a.m. EST The Citizens Life Sciences Conference on Wednesday, March 11, 2026, at 10:45 a.m. EST The live audio webcast of each presentation will be accessible on the Investors section of the.

The consensus price target hints at an 117.1% upside potential for KalVista Pharmaceuticals (KALV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the newly published International Guideline on the Diagnosis and Management of Pediatric Patients With Hereditary Angioedema recommends EKTERLY® (sebetralstat) as a first-line therapy for the acute treatment of hereditary angioedema (HAE) attacks in adolescents aged 12 years and older.1 Based on robust, high-quality evidence, including clinical trial data demonstrating con.

FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the acceptance of three abstracts for presentation at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting taking place in Philadelphia, Pennsylvania from February 27–March 2, 2026. The following poster presentations will take place on Friday, February 27 from 2:45–3:45 pm ET in the Convention Center, Level 2, Hall E: Response Drivers in Sebetral.

KalVista Pharmaceuticals retains a 'Strong Buy' rating, driven by EKTERLY's global launch and robust initial sales momentum. Company achieved $35M in Q4 2025 and $49M in full-year 2025 unaudited EKTERLY revenues, with demand in Germany matching the U.S. launch trajectory. Key upside catalyst is the KONFIDENT-KID phase 3 trial, targeting label expansion for pediatric HAE patients ages 2–11, with NDA filing expected Q3 2026.

FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Compensation Committee of KalVista's Board of Directors granted six newly-hired employees inducement options to purchase an aggregate of 96,750 shares of KalVista common stock on February 1, 2026 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stoc.

The consensus price target hints at an 116.4% upside potential for KalVista Pharmaceuticals (KALV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

The mean of analysts' price targets for KalVista Pharmaceuticals (KALV) points to an 118% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

KalVista Pharmaceuticals Inc. (NASDAQ: KALV) on Thursday reported early commercial momentum for its hereditary angioedema treatment EKTERLY, highlighting growing prescriber adoption, repeat prescriptions and expanding global access following its mid-2025 launch.